Holen Sie sich die Stockscreener-App
4.46
10.08%
-0.50
Vorhandelsmarkt:
4.36
-0.10
-2.24%
Schlusskurs vom Vortag:
$4.96
Offen:
$4.32
24-Stunden-Volumen:
9.20M
Relative Volume:
1.53
Marktkapitalisierung:
$1.22B
Einnahmen:
$8.10M
Nettoeinkommen (Verlust:
$-92.72M
KGV:
-12.49
EPS:
-0.3571
Netto-Cashflow:
$-82.52M
1W Leistung:
-8.61%
1M Leistung:
-6.30%
6M Leistung:
+72.87%
1J Leistung:
+191.50%
1-Tages-Spanne:
$3.97
$4.5599
1-Wochen-Bereich:
$3.97
$5.25
52-Wochen-Spanne:
$1.05
$5.5082
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Vergleichen Sie TSHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.46 | 1.35B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-11 | Eingeleitet | BofA Securities | Buy |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Taysha Gene Therapies Q3 net loss widens as R&D costs rise - MarketScreener
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Taysha Gene (NASDAQ: TSHA) wins FDA Breakthrough Therapy for TSHA-102 in Rett syndrome - Stock Titan
How Taysha Gene Therapies Inc. stock benefits from strong dollarJuly 2025 News Drivers & Risk Adjusted Buy/Sell Alerts - newser.com
Short interest data insights for Taysha Gene Therapies Inc.Market Sentiment Review & Free Safe Entry Trade Signal Reports - newser.com
Will Taysha Gene Therapies Inc. stock recover after recent dropWeekly Trade Analysis & Fast Gaining Stock Reports - newser.com
Can Taysha Gene Therapies Inc. hit a new high this monthWeekly Market Report & Capital Efficiency Focused Ideas - newser.com
Using Bollinger Bands to evaluate Taysha Gene Therapies Inc.Weekly Trade Review & Entry Point Confirmation Signals - newser.com
What To Expect From Taysha Gene Therapies Inc (TSHA) Q3 2025 Ear - GuruFocus
Can Taysha Gene Therapies Inc. stock sustain institutional interest2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com
What To Expect From Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings - Yahoo Finance
Is Taysha Gene Therapies Inc. stock near bottom after declineFed Meeting & Weekly High Potential Stock Alerts - newser.com
Why Taysha Gene Therapies Inc. stock is favored by top institutions2025 Key Lessons & Weekly Top Gainers Alerts - newser.com
Detecting support and resistance levels for Taysha Gene Therapies Inc.Rate Hike & Fast Entry Momentum Trade Alerts - newser.com
How institutional ownership impacts Taysha Gene Therapies Inc. stockJuly 2025 Review & Free Safe Capital Growth Stock Tips - newser.com
Will breakout in Taysha Gene Therapies Inc. lead to full recoveryMarket Movement Recap & Consistent Profit Trading Strategies - newser.com
Can momentum traders help lift Taysha Gene Therapies Inc.Quarterly Earnings Summary & Entry Point Confirmation Alerts - newser.com
Candlestick signals on Taysha Gene Therapies Inc. stock todayIPO Watch & Accurate Entry and Exit Point Alerts - newser.com
Why Taysha Gene Therapies Inc. stock is rated strong buyTrade Signal Summary & Weekly High Return Stock Forecasts - newser.com
Will a bounce in Taysha Gene Therapies Inc. offer an exitJuly 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies (TSHA) Expected to Announce Earnings on Tuesday - MarketBeat
Taysha Gene Therapies’ REVEAL Adult Study: A New Hope for Rett Syndrome? - TipRanks
Published on: 2025-10-29 21:17:59 - newser.com
Can Taysha Gene Therapies Inc. stock beat market expectations this quarterPortfolio Gains Summary & Risk Controlled Swing Alerts - fcp.pa.gov.br
Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Market Sentiment & Stock Timing and Entry Methods - fcp.pa.gov.br
Will Taysha Gene Therapies Inc. stock maintain momentum in 2025 - Fundação Cultural do Pará
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 - The Manila Times
Taysha Gene Therapies (NASDAQ: TSHA) sets Nov. 4, 8:30 a.m. ET call and webcast - Stock Titan
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Taysha Gene Therapies Inc-Aktie (TSHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Option Exercise |
0.70 |
41,150 |
28,760 |
1,206,439 |
| Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Sale |
3.23 |
200,000 |
646,000 |
1,006,439 |
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):